Mercer Global Advisors
IBRX icon

Mercer Global Advisors’s ImmunityBio IBRX Stock Holding History

Mercer Global Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Buy
13,848
+1,107
+9% +$8.38K ﹤0.01% 3383
2026
Q1 		$93.6K Sell
12,741
-826
-6% -$5.65K ﹤0.01% 3034
2025
Q4 		$26.9K Sell
13,567
-3,392
-20% -$7.68K ﹤0.01% 2814
2025
Q3 		$41.7K Sell
16,959
-19,865
-54% -$51.2K ﹤0.01% 2597
2025
Q2 		$97.2K Buy
+36,824
New +$99K ﹤0.01% 2160
2025
Q1 		– Sell
-37,006
Closed -$94.7K – 2205
2024
Q4 		$94.7K Buy
37,006
+8,359
+29% +$34.8K ﹤0.01% 2046
2024
Q3 		$103K Buy
28,647
+8,743
+44% +$40.5K ﹤0.01% 1876
2024
Q2 		$126K Buy
+19,904
New +$131K ﹤0.01% 1854

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mercer Global Advisors's IBRX Position: Q2 2026 in Review

Mercer Global Advisors increased its ImmunityBio (IBRX) stake by 8.7% in Q2 2026, buying an estimated $8.38K and bringing the position to 13,848 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

Mercer Global Advisors first reported a position in IBRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $126K in Q2 2024. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Mercer Global Advisors held 13,848 shares of ImmunityBio worth $121K as of Q2 2026.
  • Mercer Global Advisors bought 1,107 ImmunityBio shares in Q2 2026, an estimated $8.38K.
  • ImmunityBio made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3383 holding.
  • Mercer Global Advisors first reported a position in ImmunityBio in Q2 2024 and has held it in 8 quarters since.
  • Mercer Global Advisors's ImmunityBio position peaked at $126K in Q2 2024.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.